How Claritas Rx Converts Data into Patient Insights

The journey from drug development to patient access continues to be one of healthcare’s most enduring challenges. As therapies become more advanced, the complexity of ensuring that treatments reach the right patients at the right time has increased significantly.

Specialty and Rare Disease data experts at Claritas Rx have been tackling this issue since 2011, when they began enhancing how biopharmaceutical manufacturers comprehend their specialty product performance. The company has transformed from a small-channel data consultancy into a leader in patient-level data integration and analytics, serving a diverse client base that includes emerging biotechnology firms launching their first specialty products and global manufacturers with established portfolios.

This data-driven strategy has revolutionized the understanding of patient journeys through the company’s collaboration with global pharmaceutical company Servier. What started in 2020 as a focused partnership on two oncology drugs has expanded to encompass Servier’s entire cancer treatment portfolio.

Athena Uzzo, Senior Vice President of Customer Experience at Claritas Rx, characterizes the relationship as “a collaborative partnership” centered on addressing Servier’s specific business inquiries.

“We manage the data aggregation and collaborate with all of their partners across those brands, and then also provide the analytical insights,” she states.

Claritas Rx was established with a clear mission. “Our company was founded to ensure that patients with chronic and life-threatening diseases receive the support necessary to derive the maximum benefit from their therapy,” Athena explains.

To read the full article in the magazine, click HERE.